The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Ovarian Cancer MORE >>

Olaparib has been approved by the European Commission as a treatment in the maintenance setting for adult patients with advanced BRCA1/2-mutated germline and/or somatic high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response following frontline treatment with a platinum-based chemotherapy.

Latest JournalAll Journals >>

The Journal of Targeted Therapies in Cancer February 2019
The Journal of Targeted Therapies in Cancer
MORE >>
The Targeted Oncology ovarian cancer resource center provides the latest clinical updates about the disease state, with a plethora of ovarian cancer news articles covering the most up-to-date advancements in the field, as well as exclusive interviews with key ovarian cancer opinion leaders. Visitors to the site will find news that highlights both current and emerging ovarian cancer treatment options, as well as updates from the world’s most attended oncology conferences and annual meetings, including key coverage almost immediately after it is presented.

Additionally, video interviews and case studies from gynecologic oncologists and professionals specializing in ovarian cancer can be found on this page, offering expert guidance on the presentation of early ovarian cancer symptoms, tips and advice for management of the disease, and treatment options for patients. The web version of The Journal of Targeted Therapies, also found here, offers the most up-to-date data from recently completed clinical trials, analyses, and ongoing studies in patients in all stages of ovarian cancer.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.